MET and non-small cell lung carcinoma: The phase Ib study evaluated Teliso-V (2.7 mg/kg once every 21 days) plus erlotinib (150 mg once daily) in EGFR-activating mutation and c-MET+ NSCLC patients who have progressed to an EGFR TKI.